EDAP Announces Opening of two New Ablatherm-HIFU Excellence Urology Centers in the U.S.
19 Settembre 2017 - 3:16PM
University of Chicago Medicine
- Dr. A. Shalhav, Chair of Urology Surgery and Director of Robotic
Surgery Vituro Health LLC - Dr. S. Scionti, Medical Director
and Director of The Scionti Prostate Center in Sarasota, FL
LYON, France, September 19, 2017 -- EDAP TMS SA
(Nasdaq:EDAP), the global leader in therapeutic ultrasound, today
announced successful treatments performed by two excellence and
referenced Prostate U.S. centers, using Ablatherm Robotic HIFU.
Dr. Arieh Shalhav, Chair of Urology Surgery and
Director of Robotic Surgery at University of Chicago Medicine,
commented: "As surgeons, we strive to find effective treatment
options that are less disruptive to the human body and life, and
set the stage for better, and gentler ways of curing disease. Focal
HIFU fills a significant void between active surveillance - a watch
and wait approach , which can be stressful - and radical treatments
like whole gland removal, radiation or ablation. HIFU bridges
this gap and allows patients to maintain their quality of
life."
Dr. Stephen Scionti, the most experienced HIFU
urologist in the U.S. and Medical Director of Vituro Health added:
"I am captivated by Ablatherm-HIFU; the device is very user
friendly and its automatic robotized approach makes it very safe
and easy to learn and use. The friendliness of the software and the
high quality of the 7.5MHz ultrasound image facilitates treatment
in a fast, smooth and accurate manner."
Marc Oczachowski, Chief Executive Officer of
EDAP TMS, concluded: "We are honored to have such prominent
excellence centers as the University of Chicago Medicine and The
Scionti Prostate Center in Florida adopting our Ablatherm Robotic
HIFU device. As we are actively opening new HIFU sites in the U.S.,
it is very rewarding to receive immediate high satisfaction and
positive feedback from such key opinion leaders in Urology upon
performing their first Ablatherm-HIFU treatments. Such positive
live appreciation from physicians confirms Ablatherm-HIFU technical
superiority and validates our educational strategy with the close
assistance of an experienced KOL proctor."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for
high-intensity focused ultrasound (HIFU) for prostate tissue
ablation in the U.S. and for treatment of localized prostate cancer
in the rest of the world. HIFU treatment is shown to be a minimally
invasive and effective option for prostatic tissue ablation with a
low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Ablatherm-HIFU is approved for commercial distribution
in Europe and some other countries including Mexico and Canada, and
has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is
not FDA cleared yet. The Company also markets an innovative
robot-assisted HIFU device, the Focal One®, dedicated to focal
therapy of prostate cancer. Focal One® is CE marked but is not FDA
cleared. The Company also develops its HIFU technology for the
potential treatment of certain other types of tumors. EDAP TMS SA
also produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com ,
and http://www.hifu-prostate.com.
About Vituro Health
Vituro Health empowers men with comprehensive
prostate care during all stages of their lives. We arm partner
physicians with HIFU (high intensity focused ultrasound) technology
and other patient-centric, concierge services to elevate the
standard of care and patient experiences. Vituro Health serves
patients nationwide and is headquartered in Birmingham, Ala.,
with partnering physicians in Birmingham, Sarasota,
Fla., Jacksonville, Fla., Atlanta, Philadelphia, Pa.
the Washington metropolitan area, Dallas,
Tex., Las Vegas, Nev., and Phoenix, Ariz., who are
carefully selected based on their depth of experience, expertise
and dedication to achieving the highest levels of patient outcomes.
For more information and to learn about our physicians,
visit www.viturohealth.com.
Forward-Looking Statements
In addition to historical information, this
press release may contain forward-looking statements. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties, including matters
not yet known to us or not currently considered material by us, and
there can be no assurance that anticipated events will occur or
that the objectives set out will actually be achieved. Important
factors that could cause actual results to differ materially from
the results anticipated in the forward-looking statements include,
among others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
Investor Contact
CG CAPITAL Rich Cockrell 877.889.1972
investorrelations@cg.capital
Company ContactBlandine ConfortInvestor Relations / Legal
Affairs EDAP TMS SA+33 4 72 15 31 50bconfort@edap-tms.com
Grafico Azioni EDAP TMS (NASDAQ:EDAP)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni EDAP TMS (NASDAQ:EDAP)
Storico
Da Mar 2024 a Mar 2025
